Design, synthesis, and antiproliferative activity assessment of non-ATP-competitive fibroblast growth factor receptor 1 inhibitors

S. Ying; Jia Wang; C. Xu; Y. Kang; X. Zhang; L. Shi; L. Fan; Z. Wang; J. Zhou; X. Wu; J. Wu; W. Li; G. Liang

doi:10.1134/S1070363216120355

Design, synthesis, and antiproliferative activity assessment of non-ATP-competitive fibroblast growth factor receptor 1 inhibitors

作者: Ying S.¹, Wang J.¹, Xu C.¹, Kang Y.¹, Zhang X.¹, Shi L.¹, Fan L.¹, Wang Z.¹, Zhou J.¹, Wu X.¹, Wu J.¹, Li W.¹^,2, Liang G.¹
隶属关系:
1. Chemical Biology Research Center, College of Pharmaceutical Sciences
2. College of Information Science and Computer Engineering
期: 卷 86, 编号 12 (2016)
页面: 2744-2751
栏目: Article
URL: https://journals.rcsi.science/1070-3632/article/view/216870
DOI: https://doi.org/10.1134/S1070363216120355
ID: 216870

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅存取

详细
作者简介
参考
统计

详细

Fibroblast growth factor receptor 1 (FGFR1) is considered a therapeutic target for multiple cancers, including gastric cancer. FGFR1 inhibitors, being ATP competitors, can prevent the kinase domain and the downstream signaling cascade from phosphorylation and thus have the potential to treat cancers associated with aberrant FGFR1 activation. However, untargeted inhibition may cause numerous side effects. Thus, a non-ATP competitive FGFR1 inhibitor should be urgently identified and explored. In this study, we designed and synthesized 17 derivatives of nordihydroguaiaretic acid (NDGA), a known ATP-independent FGFR3 inhibitor. In the kinase activity assay, 3,5-bis(2-fluorobenzylidene)piperidin-4-one (1B) showed the highest kinase inhibitory activity among all derivatives and was thus identified as a non-ATP-competitive FGFR1 inhibitor. In the biological effect evaluation, 1B restrained the FGFR−FRS2−ERK signaling pathway in a dose-dependent manner and inhibited the growth of two gastric cancer cell lines. Overall, 1B can be considered as a potential candidate for treating gastric cancer and as an outstanding lead compound for the discovery of novel non-ATPcompetitive FGFR1 inhibitors.

关键词

antitumor activity, design and synthesis, FGFR1 inhibitors, gastric cancer, NDGA analogs, non-ATP-competitive protein kinase inhibitor

用户名
密码
记住我

忘记您的密码?	注册

用户名
密码
记住我

忘记您的密码?	注册

Design, synthesis, and antiproliferative activity assessment of non-ATP-competitive fibroblast growth factor receptor 1 inhibitors

全文:

详细

关键词

作者简介